Leki przeciwlipemiczne w prewencji i leczeniu COVID 19. Artykuł “State-of-the-Art”

Azita H. Talasaz i wsp. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol, 78 (16) 1635–1654

Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing …

Journal of the American College of Cardiology.26 października 2021

0 replies on “Leki przeciwlipemiczne w prewencji i leczeniu COVID 19. Artykuł “State-of-the-Art””